The last of around 4,500 patients was recruited in the final week of June 2008, and the three-year study will be conducted in North and South America, Europe and Asia.
Michael Novinski, president and CEO of Emisphere, said: “This Phase III study provides yet another application of our Eligen technology in the fight against osteoporosis. Safe, effective and rapid treatment will make a difference in the lives of millions of American women who are afflicted with the disease.”